{"id":56787,"date":"2026-02-10T22:35:37","date_gmt":"2026-02-10T14:35:37","guid":{"rendered":"https:\/\/flcube.com\/?p=56787"},"modified":"2026-02-10T22:35:39","modified_gmt":"2026-02-10T14:35:39","slug":"zhongsheng-pharma-licenses-ray1225-glp-1-gip-dual-agonist-to-qilu-pharma-for-144-million","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=56787","title":{"rendered":"Zhongsheng Pharma Licenses RAY1225 GLP-1\/GIP Dual Agonist to Qilu Pharma for $144 Million"},"content":{"rendered":"\n<p><strong>Guangdong Zhongsheng Pharmaceutical Co., Ltd<\/strong> (<strong><a href=\"https:\/\/www.google.com\/finance\/quote\/002317:SHE\">SHE: 002317<\/a><\/strong>) has entered a <strong>strategic licensing agreement<\/strong> with <strong>Qilu Pharmaceutical Co., Ltd.<\/strong> for <strong>RAY1225<\/strong>, an <strong>ultra-long-acting dual GLP-1\/GIP receptor agonist<\/strong>. The deal, valued at up to <strong>RMB 1 billion (USD 144 million)<\/strong>, grants Qilu Pharma <strong>China commercialization rights<\/strong> while Zhongsheng retains <strong>IP ownership<\/strong> and continues to lead <strong>clinical development<\/strong> for obesity, type 2 diabetes, and related metabolic indications.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-transaction-structure\">Transaction Structure<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Element<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Licensor<\/strong><\/td><td>Guangdong Zhongsheng Pharmaceutical (SHE: 002317)<\/td><\/tr><tr><td><strong>Licensee<\/strong><\/td><td>Qilu Pharmaceutical Co., Ltd.<\/td><\/tr><tr><td><strong>Asset<\/strong><\/td><td>RAY1225 \u2013 GLP-1\/GIP dual receptor agonist<\/td><\/tr><tr><td><strong>Territory<\/strong><\/td><td>Greater China (mainland, Hong Kong, Macau, Taiwan)<\/td><\/tr><tr><td><strong>Upfront Payment<\/strong><\/td><td>RMB 200 million (USD 29 million)<\/td><\/tr><tr><td><strong>Milestone Payments<\/strong><\/td><td>Up to RMB 800 million (USD 116 million)<\/td><\/tr><tr><td><strong>Total Deal Value<\/strong><\/td><td>RMB 1 billion (USD 144 million)<\/td><\/tr><tr><td><strong>Royalties<\/strong><\/td><td>Double-digit percentage of net sales post-launch<\/td><\/tr><tr><td><strong>IP Ownership<\/strong><\/td><td>Retained by Zhongsheng Pharma<\/td><\/tr><tr><td><strong>Development Responsibility<\/strong><\/td><td>Zhongsheng continues clinical development and registration<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-product-profile-amp-clinical-pipeline\">Product Profile &amp; Clinical Pipeline<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Feature<\/th><th>RAY1225 Specification<\/th><th>Competitive Advantage<\/th><\/tr><\/thead><tbody><tr><td><strong>Mechanism<\/strong><\/td><td>Dual agonist: GLP-1 + GIP receptors<\/td><td>Enhanced glycemic control and weight loss vs. GLP-1 monotherapy<\/td><\/tr><tr><td><strong>Duration<\/strong><\/td><td><strong>Ultra-long-acting; bi-weekly injection<\/strong><\/td><td>Reduced injection frequency vs. weekly semaglutide<\/td><\/tr><tr><td><strong>Administration<\/strong><\/td><td>Subcutaneous injection every 14 days<\/td><td>Improved patient compliance, reduced healthcare burden<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Phase III Trial<\/th><th>Indication<\/th><th>Design<\/th><th>Status<\/th><\/tr><\/thead><tbody><tr><td><strong>REBUILDING-2<\/strong><\/td><td>Obesity\/overweight (Chinese patients)<\/td><td>Safety and efficacy evaluation<\/td><td><strong>Enrollment completed<\/strong><\/td><\/tr><tr><td><strong>SHINING-3<\/strong><\/td><td>Type 2 diabetes<\/td><td>RAY1225 + oral hypoglycemics <strong>vs. semaglutide<\/strong><\/td><td><strong>Enrollment completed<\/strong><\/td><\/tr><tr><td><strong>SHINING-2<\/strong><\/td><td>Type 2 diabetes<\/td><td>RAY1225 monotherapy <strong>vs. placebo<\/strong><\/td><td><strong>Enrollment completed<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-positioning-amp-market-context\">Strategic Positioning &amp; Market Context<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>China GLP-1 Market Explosion:<\/strong> Domestic obesity and diabetes therapeutics market projected to exceed <strong>$50 billion by 2030<\/strong>; semaglutide (Novo Nordisk) and tirzepatide (Eli Lilly) face <strong>supply constraints and pricing pressure<\/strong>, creating window for ultra-long-acting alternatives.<\/li>\n\n\n\n<li><strong>Bi-Weekly Differentiation:<\/strong> RAY1225&#8217;s <strong>14-day dosing interval<\/strong> vs. <strong>weekly semaglutide<\/strong> and <strong>tirzepatide<\/strong> offers <strong>compliance advantage<\/strong> in chronic disease management, potentially capturing <strong>patients with injection fatigue<\/strong> and <strong>healthcare systems seeking reduced nursing costs<\/strong>.<\/li>\n\n\n\n<li><strong>Dual Agonist Efficacy:<\/strong> GLP-1\/GIP mechanism demonstrated <strong>superior HbA1c reduction and weight loss<\/strong> in global trials (SURPASS program); RAY1225 positions as <strong>domestic tirzepatide alternative<\/strong> with localized manufacturing and regulatory pathway.<\/li>\n\n\n\n<li><strong>Partnership Logic:<\/strong> Qilu Pharma brings <strong>established diabetes commercial infrastructure<\/strong> and <strong>hospital formulary relationships<\/strong>; Zhongsheng monetizes R&amp;D investment while retaining <strong>downside protection via milestones and royalties<\/strong>.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-amp-development-outlook\">Financial &amp; Development Outlook<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Phase<\/th><th>Activity<\/th><th>Timeline<\/th><\/tr><\/thead><tbody><tr><td><strong>Current<\/strong><\/td><td>Three Phase III trials enrollment completed<\/td><td>Q1 2026<\/td><\/tr><tr><td><strong>Near-term<\/strong><\/td><td>Phase III data readout and NDA submission<\/td><td>2026-2027<\/td><\/tr><tr><td><strong>Regulatory<\/strong><\/td><td>NMPA approval and pricing negotiation<\/td><td>2027-2028<\/td><\/tr><tr><td><strong>Commercial<\/strong><\/td><td>Qilu Pharma launch with Zhongsheng royalty stream<\/td><td>2028+<\/td><\/tr><tr><td><strong>Expansion<\/strong><\/td><td>Potential cardiovascular outcome trials and MASH indication<\/td><td>Post-approval<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding RAY1225 Phase III clinical outcomes, NMPA approval timelines, and commercial performance of the Zhongsheng-Qilu partnership. Actual results may differ due to competitive dynamics with Novo Nordisk and Eli Lilly, pricing pressure in China&#8217;s NRDL negotiations, and manufacturing scale-up challenges for ultra-long-acting biologics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) has entered a strategic licensing agreement with Qilu&#8230;<\/p>\n","protected":false},"author":1,"featured_media":56788,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[4361,208,1197,399],"class_list":["post-56787","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-hot-targets","tag-qilu-pharmaceutical","tag-she-002317","tag-zhongsheng-pharmaceutical"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Zhongsheng Pharma Licenses RAY1225 GLP-1\/GIP Dual Agonist to Qilu Pharma for $144 Million - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) has entered a strategic licensing agreement with Qilu Pharmaceutical Co., Ltd. for RAY1225, an ultra-long-acting dual GLP-1\/GIP receptor agonist. The deal, valued at up to RMB 1 billion (USD 144 million), grants Qilu Pharma China commercialization rights while Zhongsheng retains IP ownership and continues to lead clinical development for obesity, type 2 diabetes, and related metabolic indications.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=56787\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Zhongsheng Pharma Licenses RAY1225 GLP-1\/GIP Dual Agonist to Qilu Pharma for $144 Million\" \/>\n<meta property=\"og:description\" content=\"Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) has entered a strategic licensing agreement with Qilu Pharmaceutical Co., Ltd. for RAY1225, an ultra-long-acting dual GLP-1\/GIP receptor agonist. The deal, valued at up to RMB 1 billion (USD 144 million), grants Qilu Pharma China commercialization rights while Zhongsheng retains IP ownership and continues to lead clinical development for obesity, type 2 diabetes, and related metabolic indications.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=56787\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-10T14:35:37+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-10T14:35:39+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/1002.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56787#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56787\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Zhongsheng Pharma Licenses RAY1225 GLP-1\\\/GIP Dual Agonist to Qilu Pharma for $144 Million\",\"datePublished\":\"2026-02-10T14:35:37+00:00\",\"dateModified\":\"2026-02-10T14:35:39+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56787\"},\"wordCount\":460,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56787#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/1002.webp\",\"keywords\":[\"Hot targets\",\"Qilu Pharmaceutical\",\"SHE: 002317\",\"Zhongsheng Pharmaceutical\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=56787#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56787\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=56787\",\"name\":\"Zhongsheng Pharma Licenses RAY1225 GLP-1\\\/GIP Dual Agonist to Qilu Pharma for $144 Million - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56787#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56787#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/1002.webp\",\"datePublished\":\"2026-02-10T14:35:37+00:00\",\"dateModified\":\"2026-02-10T14:35:39+00:00\",\"description\":\"Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) has entered a strategic licensing agreement with Qilu Pharmaceutical Co., Ltd. for RAY1225, an ultra-long-acting dual GLP-1\\\/GIP receptor agonist. The deal, valued at up to RMB 1 billion (USD 144 million), grants Qilu Pharma China commercialization rights while Zhongsheng retains IP ownership and continues to lead clinical development for obesity, type 2 diabetes, and related metabolic indications.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56787#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=56787\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56787#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/1002.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/1002.webp\",\"width\":1080,\"height\":608,\"caption\":\"Zhongsheng Pharma Licenses RAY1225 GLP-1\\\/GIP Dual Agonist to Qilu Pharma for $144 Million\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56787#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Zhongsheng Pharma Licenses RAY1225 GLP-1\\\/GIP Dual Agonist to Qilu Pharma for $144 Million\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Zhongsheng Pharma Licenses RAY1225 GLP-1\/GIP Dual Agonist to Qilu Pharma for $144 Million - Insight, China&#039;s Pharmaceutical Industry","description":"Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) has entered a strategic licensing agreement with Qilu Pharmaceutical Co., Ltd. for RAY1225, an ultra-long-acting dual GLP-1\/GIP receptor agonist. The deal, valued at up to RMB 1 billion (USD 144 million), grants Qilu Pharma China commercialization rights while Zhongsheng retains IP ownership and continues to lead clinical development for obesity, type 2 diabetes, and related metabolic indications.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=56787","og_locale":"en_US","og_type":"article","og_title":"Zhongsheng Pharma Licenses RAY1225 GLP-1\/GIP Dual Agonist to Qilu Pharma for $144 Million","og_description":"Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) has entered a strategic licensing agreement with Qilu Pharmaceutical Co., Ltd. for RAY1225, an ultra-long-acting dual GLP-1\/GIP receptor agonist. The deal, valued at up to RMB 1 billion (USD 144 million), grants Qilu Pharma China commercialization rights while Zhongsheng retains IP ownership and continues to lead clinical development for obesity, type 2 diabetes, and related metabolic indications.","og_url":"https:\/\/flcube.com\/?p=56787","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-02-10T14:35:37+00:00","article_modified_time":"2026-02-10T14:35:39+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/1002.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=56787#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=56787"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Zhongsheng Pharma Licenses RAY1225 GLP-1\/GIP Dual Agonist to Qilu Pharma for $144 Million","datePublished":"2026-02-10T14:35:37+00:00","dateModified":"2026-02-10T14:35:39+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=56787"},"wordCount":460,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=56787#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/1002.webp","keywords":["Hot targets","Qilu Pharmaceutical","SHE: 002317","Zhongsheng Pharmaceutical"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=56787#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=56787","url":"https:\/\/flcube.com\/?p=56787","name":"Zhongsheng Pharma Licenses RAY1225 GLP-1\/GIP Dual Agonist to Qilu Pharma for $144 Million - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=56787#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=56787#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/1002.webp","datePublished":"2026-02-10T14:35:37+00:00","dateModified":"2026-02-10T14:35:39+00:00","description":"Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) has entered a strategic licensing agreement with Qilu Pharmaceutical Co., Ltd. for RAY1225, an ultra-long-acting dual GLP-1\/GIP receptor agonist. The deal, valued at up to RMB 1 billion (USD 144 million), grants Qilu Pharma China commercialization rights while Zhongsheng retains IP ownership and continues to lead clinical development for obesity, type 2 diabetes, and related metabolic indications.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=56787#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=56787"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=56787#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/1002.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/1002.webp","width":1080,"height":608,"caption":"Zhongsheng Pharma Licenses RAY1225 GLP-1\/GIP Dual Agonist to Qilu Pharma for $144 Million"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=56787#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Zhongsheng Pharma Licenses RAY1225 GLP-1\/GIP Dual Agonist to Qilu Pharma for $144 Million"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/1002.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56787","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=56787"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56787\/revisions"}],"predecessor-version":[{"id":56790,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56787\/revisions\/56790"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/56788"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=56787"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=56787"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=56787"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}